AcelRx Pharma (ACRX) Misses Q2 EPS by 2c

AcelRx Pharma (NASDAQ: ACRX) reported Q2 EPS of ($0.24), $0.02 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $4.53 million versus the consensus estimate of $2.17 million.

For earnings history and earnings-related data on AcelRx Pharma (ACRX) click here.

You May Also Be Interested In

• Growth isn't weak enough to truly undercut inflation pressures - BMO
• American Express (AXP) down despite beating Q1 estimates on top and bottom lines
• BancFirst Corp. (BANF) Tops Q1 EPS by 11c